{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:53:48Z","timestamp":1785336828888,"version":"3.55.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1097\/ico.0b013e31802e3ce4","type":"journal-article","created":{"date-parts":[[2006,12,22]],"date-time":"2006-12-22T09:10:46Z","timestamp":1166778646000},"page":"34-41","source":"Crossref","is-referenced-by-count":52,"title":["Relationship Between Travoprost and Central Corneal Thickness in Ocular Hypertension and Open-Angle Glaucoma"],"prefix":"10.1097","volume":"26","author":[{"given":"Paul J","family":"Harasymowycz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demosthenes G","family":"Papamatheakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marguerite","family":"Ennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith D","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"Suppl","key":"R1-7-20210204","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ajo.2004.04.058","article-title":"An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma.","volume":"138","author":"Friedman","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"R2-7-20210204","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0002-9394(03)00098-9","article-title":"the XLT study group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized masked-evaluator multicenter study.","volume":"135","author":"Parrish","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"R3-7-20210204","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/00055735-200004000-00008","article-title":"The mechanism of action of prostaglandins on uveoscleral outflow.","volume":"11","author":"Schachtschabel","year":"2000","journal-title":"Curr Opin Ophthalmol"},{"key":"R4-7-20210204","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archopht.117.6.794","article-title":"Topical prostaglandin F2a treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway.","volume":"117","author":"Sagara","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"R5-7-20210204","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1089\/108076803322660422","article-title":"Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells.","volume":"19","author":"Sharif","year":"2003","journal-title":"J Ocul Pharmacol Ther"},{"key":"R6-7-20210204","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1185\/030079904125004529","article-title":"Concomitant administration of travoprost and brinzolamide versus fixed latanoprost\/timolol combined therapy: three-month comparison of efficacy and safety.","volume":"20","author":"Martinez-de-la-Casa","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"R7-7-20210204","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1185\/030079904125004448","article-title":"the START Study Group. Ocular hypotensive efficacy of travoprost in patients unsuccessfully treated with latanoprost.","volume":"20","author":"Kaback","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"R8-7-20210204","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1177\/112067210401400509","article-title":"the Swiss Start Study Group. Intraocular pressure lowering efficacy of travoprost.","volume":"14","author":"Przydryga","year":"2004","journal-title":"Eur J Ophthalmol"},{"key":"R9-7-20210204","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0002-9394(02)01827-5","article-title":"A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma.","volume":"135","author":"Noecker","year":"2003","journal-title":"Am J Ophthalmol"},{"issue":"Suppl","key":"R10-7-20210204","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0039-6257(02)00327-2","article-title":"Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs.","volume":"47","author":"Eisenberg","year":"2002","journal-title":"Surv Ophthalmol"},{"key":"R11-7-20210204","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF02850202","article-title":"Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertension.","volume":"20","author":"Netland","year":"2003","journal-title":"Adv Ther"},{"key":"R12-7-20210204","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0002-9394(01)01177-1","article-title":"Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.","volume":"132","author":"Netland","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"R13-7-20210204","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1001\/archopht.120.6.714","article-title":"The ocular hypertension treatment study: baseline factors that predict the onset of primary open-angle glaucoma.","volume":"120","author":"Gordon","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"R14-7-20210204","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/archopht.122.1.17","article-title":"Central corneal thickness as a risk factor for advanced glaucoma damage.","volume":"122","author":"Herndon","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"R15-7-20210204","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1001\/archopht.122.9.1270","article-title":"Clinical significance of central corneal thickness in the management of glaucoma.","volume":"122","author":"Shih","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"R16-7-20210204","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archopht.121.1.48","article-title":"Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial.","volume":"121","author":"Leske","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R17-7-20210204","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0021-5155(02)00667-6","article-title":"Influence of dorzolamide on corneal endothelium.","volume":"47","author":"Inoue","year":"2003","journal-title":"Jpn J Ophthalmol"},{"key":"R18-7-20210204","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1055\/s-2004-81361","article-title":"Impact of prostaglandin-F2-analogues and carbonic anhydrase inhibitors on central corneal thickness-a cross-sectional study on 403 eyes.","volume":"221","author":"Viestenz","year":"2004","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"R19-7-20210204","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0161-6420(00)00531-5","article-title":"the Latanoprost Corneal Effects Study Group. Comparison of the corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol: a double-masked randomized, one-year study.","volume":"108","author":"Lass","year":"2001","journal-title":"Ophthalmology"},{"key":"R21-7-20210204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00031305.1996.10473533","article-title":"The use and misuse of orthogonal regression in linear errors-in-variables models.","volume":"50","author":"Carroll","year":"1996","journal-title":"Am Stat"},{"key":"R22-7-20210204","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/archopht.122.2.185","article-title":"Crossover comparison of timolol and latanoprost in chronic primary angle-closure glaucoma.","volume":"122","author":"Sihota","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"R23-7-20210204","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1600-0420.2004.00358.x","article-title":"A comparison of the effects of dorzolamide\/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients.","volume":"82","author":"Januleviciene","year":"2004","journal-title":"Acta Ophthalmol Scand"},{"key":"R25-7-20210204","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/bmj.309.6957.780","article-title":"Statistics notes: some examples of regression towards the mean.","volume":"309","author":"Bland","year":"1994","journal-title":"BMJ"},{"key":"R26-7-20210204","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F","article-title":"Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians.","volume":"19","author":"Carpenter","year":"2000","journal-title":"Stat Med"},{"key":"R27-7-20210204","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/096228029700600203","article-title":"The impact and implication of regression to the mean on the design and analysis of medical investigations.","volume":"6","author":"Chuang-Stein","year":"1997","journal-title":"Stat Methods Med Res"},{"issue":"Suppl","key":"R28-7-20210204","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/0197-2456(95)90526-B","article-title":"A protocol to minimize bias and regression to the mean in measurement of intraocular pressure.","volume":"16","author":"Gordon","year":"1995","journal-title":"Control Clin Trials"},{"key":"R29-7-20210204","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ophtha.2004.08.020","article-title":"Central corneal thickness: will one measurement suffice?","volume":"112","author":"Wickham","year":"2005","journal-title":"Ophthalmology"},{"key":"R30-7-20210204","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/eye.1995.100","article-title":"Overexpression of gelatinase A activity in keratoconus.","volume":"9","author":"Smith","year":"1995","journal-title":"Eye"},{"key":"R31-7-20210204","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1076\/ceyr.22.3.198.5515","article-title":"Latanoprost and matrix metalloproteinase-1 in human choroid organ cultures.","volume":"22","author":"Wang","year":"2001","journal-title":"Curr Eye Res"},{"key":"R32-7-20210204","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.ajo.2004.07.036","article-title":"the Ocular Hypoertension Treatment study (OHTS) Groups. Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study.","volume":"138","author":"Brandt","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"R33-7-20210204","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0002-9394(00)00930-2","article-title":"Washout periods for brimonidine 0.2% and latanoprost 0.005%.","volume":"131","author":"Stewart","year":"2001","journal-title":"Am J Ophthalmol"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00003226-200701000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T18:02:19Z","timestamp":1736704939000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003226-200701000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e31802e3ce4","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}